Phospho-ATF4 (Ser219) Antibody

What is the functional significance of ATF4 phosphorylation at Ser219?

ATF4 phosphorylation at Ser219 is a critical regulatory mechanism in synaptic plasticity pathways. This phosphorylation event occurs within a specific sequence motif (DSGXXXS) that serves as a recognition site for β-TrCP, a component of the SCF ubiquitin ligase complex . During chemically induced long-term potentiation (cLTP), pSer219-ATF4 levels initially increase, peaking at approximately 20-25 minutes post-induction, followed by a subsequent decrease to baseline levels by 30 minutes . This phosphorylation-dependent degradation of ATF4 is crucial for relieving transcriptional repression on CREB-dependent genes, such as brain-derived neurotrophic factor (BDNF), thereby facilitating gene expression required for long-term synaptic plasticity .

What kinase is responsible for phosphorylating ATF4 at Ser219?

The phosphorylation of ATF4 at Ser219 is primarily mediated by cAMP-dependent protein kinase (PKA) . Research has demonstrated this through selective inhibition studies using hippocampal slice preparations. When slices were treated with the PKA inhibitor KT5720 prior to cLTP induction, a significant attenuation of Ser219 phosphorylation was observed . In contrast, inhibitors of other kinases known to be involved in synaptic plasticity, such as extracellular signal-regulated kinase (ERK, inhibited by U0126) and cGMP-dependent protein kinase (PKG, inhibited by KT5823), did not prevent ATF4 phosphorylation at Ser219 . These findings conclusively establish PKA as the primary kinase responsible for this specific phosphorylation event during synaptic plasticity.

How is phosphorylated ATF4 (Ser219) detected in experimental systems?

Phosphorylated ATF4 at Ser219 can be detected using specialized antibodies that recognize this specific phosphorylation site. These antibodies are typically rabbit polyclonal antibodies raised against synthetic peptides containing the phosphorylated Ser219 residue within the human ATF4 sequence . Common experimental methods include:

• Western Blotting (WB): Typically performed at dilutions of 1:500-1:2000

• ELISA: Performed at higher dilutions, typically 1:10000

• Immunohistochemistry/Immunofluorescence: Used with confocal microscopy to visualize subcellular localization, often paired with nuclear counterstains like TO-PRO-3

For optimal results, these antibodies are formulated in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide and should be stored at -20°C with avoidance of repeated freeze/thaw cycles .

How does the proteasome-mediated degradation of phosphorylated ATF4 (Ser219) regulate gene expression during synaptic plasticity?

The proteasome-mediated degradation of phosphorylated ATF4 represents a sophisticated molecular switch controlling gene expression during synaptic plasticity. Upon phosphorylation at Ser219 by PKA, ATF4 becomes a substrate for the SCFβ-TrCP ubiquitin ligase complex, which targets it for proteasomal degradation . This degradation mechanism has been experimentally verified using the proteasome inhibitor β-lactone, which prevents the decrease in pSer219-ATF4 typically observed 30 minutes after cLTP induction .

The timing of this degradation is critical and precisely coordinated with gene expression patterns. Research has shown that the maximum reduction in ATF4 levels coincides with increased mRNA expression of brain-derived neurotrophic factor (BDNF), an immediate-early gene whose transcription is driven by CREB . This temporal relationship suggests a direct mechanistic link where ATF4 degradation relieves transcriptional repression on CREB-dependent genes, enabling the expression of plasticity-related proteins.

The following experimental observations support this model:

This tightly regulated degradation pathway represents a point of convergence for multiple signaling cascades and may serve as a potential therapeutic target for disorders affecting synaptic plasticity and memory formation .

What is the role of neddylation in regulating phosphorylated ATF4 (Ser219) degradation, and how can this be experimentally manipulated?

Neddylation plays a crucial role in the regulation of phosphorylated ATF4 degradation through its control of SCF ubiquitin ligase activity. Neddylation involves the covalent attachment of the small protein NEDD8 to the cullin subunit of SCF ligases, a process essential for their enzymatic activation .

This regulatory mechanism can be experimentally manipulated using the small molecule inhibitor MLN4924 (pevonedistat), which selectively inhibits the NEDD8-activating enzyme (NAE) . Research has demonstrated that pretreatment of hippocampal slices with MLN4924 prior to cLTP induction significantly inhibits ATF4 degradation, resulting in accumulation of phosphorylated ATF4 . This finding provides compelling evidence that the SCF ubiquitin ligase responsible for ATF4 ubiquitination is likely to be SCFβ-TrCP.

The experimental approach to investigate neddylation's role typically follows this protocol:

• Pretreatment of hippocampal slices with MLN4924 during the recovery period (typically the second hour)

• Induction of cLTP

• Collection of slices at 25 minutes post-induction

• Immunohistochemical analysis using anti-pSer219-ATF4 antibodies

• Quantification of immunofluorescence intensity

Quantified results typically show:

• Control conditions: Baseline pSer219-ATF4 levels

• cLTP alone: Elevated pSer219-ATF4 at 20 min, decreasing by 25-30 min

• cLTP + MLN4924: Significantly higher pSer219-ATF4 levels maintained at 25-30 min

These findings highlight neddylation as a potential point of intervention for modulating ATF4-dependent transcriptional regulation in neuronal systems .

How do the phosphorylation dynamics of ATF4 at Ser219 correlate with other phosphorylation events in the protein?

The phosphorylation of ATF4 at Ser219 is part of a complex phosphorylation cascade that regulates its stability and function. While Ser219 phosphorylation is primary, additional phosphorylation events at Thr213, Ser224, Ser231, Ser235, and Ser248 further modulate the interaction between ATF4 and the β-TrCP component of the SCF ubiquitin ligase . These additional phosphorylation sites create a cumulative negative charge that enhances β-TrCP binding affinity and subsequent degradation.

The temporal dynamics of these multiple phosphorylation events follow a specific pattern:

• Initial phosphorylation at Ser219 by PKA during early stages of cLTP (peaking at 20-25 minutes)

• This primary phosphorylation event creates a priming site for subsequent phosphorylations

• Additional phosphorylation events at surrounding residues further stabilize the interaction with β-TrCP

• The fully phosphorylated form is efficiently recognized by the SCFβ-TrCP complex, leading to ubiquitination and proteasomal degradation

This hierarchical phosphorylation pattern represents a sophisticated molecular timer that precisely controls the duration of ATF4 activity as a transcriptional repressor. Researchers investigating these dynamics typically employ phospho-specific antibodies for each site in combination with phosphatase inhibitors and time-course experiments to map the precise sequence and timing of these events .

What controls should be included when using Phospho-ATF4 (Ser219) antibodies in experimental setups?

When designing experiments with Phospho-ATF4 (Ser219) antibodies, incorporating appropriate controls is essential for result validation. A comprehensive control strategy should include:

Essential Controls:

• Non-phosphorylated control: Samples treated with phosphatase to remove phosphorylation at Ser219, demonstrating antibody specificity for the phosphorylated form

• Time-matched controls: Parallel samples not subjected to stimulation (e.g., cLTP), but processed identically at the same timepoints

• Blocking peptide control: Pre-incubation of the antibody with the phosphorylated peptide immunogen to demonstrate binding specificity

• Phosphorylation-defective mutant: Cells expressing S219A mutant ATF4 to confirm antibody specificity

Additional Validation Controls:

• Kinase inhibitor controls: Samples treated with PKA inhibitors (e.g., KT5720) to prevent Ser219 phosphorylation

• Proteasome inhibitor positive control: Samples treated with β-lactone to accumulate phosphorylated ATF4, providing a strong positive signal

• Cross-reactivity assessment: Testing against proteins with similar phosphorylation motifs to ensure specificity

Experimental design should include systematic timepoint collection (e.g., every 5 minutes during a 30-minute post-stimulation window) to capture the dynamic changes in phosphorylation state, which peaks at approximately 20-25 minutes after cLTP induction before declining .

How can researchers optimize immunohistochemical detection of phosphorylated ATF4 (Ser219) in brain tissue sections?

Optimizing immunohistochemical detection of phosphorylated ATF4 (Ser219) in brain tissue requires careful attention to several critical parameters:

Tissue Preparation:

• Rapid fixation is essential to preserve phosphorylation state (preferably within minutes of tissue collection)

• Optimal fixation using 4% paraformaldehyde for 24-48 hours, followed by cryoprotection in sucrose gradients

• Thin sectioning (typically 20-40 μm) to ensure antibody penetration throughout the tissue

Antigen Retrieval:

• Heat-mediated antigen retrieval in citrate buffer (pH 6.0) for 10-20 minutes

• Addition of phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) to all buffers to prevent dephosphorylation during processing

Staining Protocol Optimization:

• Extended blocking in 5-10% normal serum with 0.1-0.3% Triton X-100 for 1-2 hours at room temperature

• Primary antibody incubation at optimal dilutions (typically 1:200-1:500) for 24-48 hours at 4°C

• Nuclear counterstaining with TO-PRO-3 or DAPI to facilitate subcellular localization assessment

• Use of fluorophore-conjugated secondary antibodies with minimal spectral overlap with other channels

Signal Quantification:

• Consistent image acquisition parameters across all experimental conditions

• Standardized regions of interest (ROIs) for quantification

• Normalization to nuclear counterstain intensity

• Blind analysis to prevent experimental bias

Studies tracking pSer219-ATF4 dynamics have successfully employed these approaches to detect the significant increase in phosphorylation at 20-25 minutes post-cLTP induction, followed by the decrease at 30 minutes due to proteasomal degradation .

What approaches can resolve contradictory findings when studying phosphorylated ATF4 (Ser219) degradation mechanisms?

Resolving contradictory findings in phosphorylated ATF4 (Ser219) degradation research requires systematic troubleshooting and careful experimental design. Several approaches can help address discrepancies:

Methodological Standardization:

• Standardize experimental conditions across laboratories, including:

  • Tissue preparation protocols (fixation time, buffer composition)

  • Antibody sources, clones, and working dilutions

  • Quantification methods and threshold settings

Comprehensive Mechanistic Analysis:

• Employ multiple, complementary techniques to assess the same parameter:

  • Combine immunohistochemistry, Western blotting, and ELISA measurements

  • Use both pharmacological inhibitors and genetic approaches (siRNA, CRISPR)

  • Validate findings with in vivo and in vitro models

Timeline Resolution:

• Implement high-resolution temporal sampling (e.g., 5-minute intervals as in )

• Use pulse-chase experiments to track specific protein populations

• Employ live imaging with phospho-sensitive fluorescent reporters when possible

Contradiction-Specific Experiments:

• For conflicting findings on the role of specific kinases:

  • Test multiple inhibitors with different mechanisms of action

  • Combine kinase inhibition with phosphomimetic ATF4 mutants

  • Perform in vitro kinase assays using purified components

• For discrepancies in degradation mechanisms:

  • Combine proteasome inhibitors (β-lactone) with neddylation inhibitors (MLN4924)

  • Immunoprecipitate ATF4 and analyze ubiquitination patterns

  • Perform pulse-chase experiments with cycloheximide to track protein half-life

• For contradictions in downstream effects:

  • Analyze multiple CREB-regulated genes beyond BDNF

  • Perform ChIP assays to assess ATF4 binding to specific promoters

  • Use reporter assays to measure transcriptional activity directly

A comprehensive approach combining these strategies has successfully resolved apparent contradictions, such as clarifying that PKA (not PKG or ERK) is the primary kinase responsible for ATF4 Ser219 phosphorylation during cLTP .

How can researchers distinguish between basal and induced phosphorylation of ATF4 at Ser219 in complex neuronal systems?

Distinguishing between basal and induced phosphorylation of ATF4 at Ser219 in complex neuronal systems requires sophisticated experimental approaches that can detect subtle changes in phosphorylation state with high sensitivity and specificity:

Quantitative Techniques:

• Phospho-specific flow cytometry: Allows single-cell resolution analysis of phosphorylation states in heterogeneous neuronal populations

• Phosphoproteomics with targeted mass spectrometry: Enables absolute quantification of phosphorylated and non-phosphorylated ATF4 species

• Super-resolution microscopy: Permits subcellular localization of phosphorylated ATF4 at nanometer resolution

Experimental Design Strategies:

• Temporal profiling: Systematic collection of samples at short intervals (every 5 minutes) reveals the dynamic changes in phosphorylation state

• Pharmacological manipulation: Use of specific activators and inhibitors of the PKA pathway to modulate phosphorylation levels

• Subregion microdissection: Isolation of specific hippocampal subregions (CA1, CA3, DG) for region-specific analysis

Analytical Approaches:

• Ratiometric analysis: Measuring the ratio of phosphorylated to total ATF4 provides a normalized metric independent of total protein levels

• Kinetic modeling: Mathematical modeling of the phosphorylation/dephosphorylation kinetics helps distinguish between different regulatory scenarios

• Single-molecule tracking: Visualizing individual ATF4 molecules and their fate after phosphorylation

Research has shown that basal phosphorylation of ATF4 at Ser219 is maintained at low levels, with significant increases occurring approximately 15 minutes after cLTP induction (173.9% ± 5.9% compared to control: 99.2% ± 7.6%) . This temporal profile, with peak phosphorylation at 20-25 minutes followed by a decrease at 30 minutes, provides a characteristic signature that distinguishes stimulus-induced phosphorylation from basal fluctuations .

What methodological approaches can determine the precise sequence of ATF4 phosphorylation events during synaptic plasticity?

Determining the precise sequence of ATF4 phosphorylation events during synaptic plasticity requires sophisticated methodological approaches that can track multiple phosphorylation sites with high temporal resolution:

Advanced Technical Approaches:

• Multiplexed phospho-specific antibody arrays: Simultaneous detection of multiple phosphorylation sites using antibody panels specific for each phosphorylation site (Ser219, Thr213, Ser224, Ser231, Ser235, Ser248)

• Mass spectrometry-based phosphoproteomic analysis:

  • Parallel reaction monitoring for targeted analysis of specific phosphopeptides

  • SILAC or TMT labeling for quantitative comparison across timepoints

  • Phosphopeptide enrichment using TiO₂ or IMAC to enhance detection sensitivity

• Site-specific phosphorylation mutants:

  • Creation of single and combinatorial phosphorylation site mutants (S→A and S→D/E)

  • Analysis of interdependence between sites through sequential mutation

Temporal Resolution Strategies:

• Rapid sample collection and flash-freezing at precisely timed intervals

• Use of phosphatase inhibitor cocktails in all buffers to prevent artificial dephosphorylation

• Kinetic analysis with mathematical modeling to infer sequence from partial temporal data

Validation Approaches:

• In vitro kinase assays with purified PKA and other kinases to determine site preference order

• Correlation between phosphorylation at different sites and functional outcomes (e.g., ubiquitination, degradation)

• Development of biosensors for real-time tracking of phosphorylation events

Research suggests that phosphorylation at Ser219 by PKA is a primary event, which then facilitates subsequent phosphorylation at additional sites . This hierarchical pattern creates a sequential phosphorylation cascade that ultimately leads to enhanced recognition by β-TrCP and subsequent degradation . The precise mapping of this sequence has significant implications for understanding the molecular logic governing the timing of ATF4 degradation during synaptic plasticity.

How can researchers investigate the cross-talk between ATF4 phosphorylation at Ser219 and other post-translational modifications?

Investigating the cross-talk between ATF4 phosphorylation at Ser219 and other post-translational modifications (PTMs) requires integrated approaches that can detect multiple modification types simultaneously and assess their functional interactions:

Multi-Dimensional PTM Analysis:

• Integrated PTM profiling:

  • Combined phospho/ubiquitin enrichment strategies to capture both modifications

  • Sequential immunoprecipitation with modification-specific antibodies

  • Mass spectrometry analysis with multi-notch MS3 for combined PTM detection

• Site-specific mutant panels:

  • Creation of combinatorial mutants affecting phosphorylation, ubiquitination, and other PTMs

  • Complementation assays to determine functional hierarchy of modifications

  • Domain-specific mutation analysis to identify interdomain regulatory mechanisms

Mechanistic Investigation Approaches:

• Pharmacological dissection:

  • Combined use of kinase inhibitors (KT5720 for PKA), phosphatase inhibitors, proteasome inhibitors (β-lactone), and neddylation inhibitors (MLN4924)

  • Time-course studies with staggered inhibitor application to determine sequence dependency

  • Dose-response studies to identify thresholds for modification cross-talk

• Protein interaction studies:

  • Proximity ligation assays to detect interactions between differentially modified ATF4 species and regulatory proteins

  • BioID or APEX2 proximity labeling to identify the modification-dependent interactome

  • FRET-based biosensors to detect conformational changes induced by specific modifications

Functional Consequence Analysis:

• Reporter gene assays with promoters containing CRE elements to measure transcriptional repression capacity

• ChIP-seq analysis to determine genomic binding patterns of differentially modified ATF4

• Proteomic turnover analysis using pulse-chase methods to measure half-life changes associated with specific modification patterns

Research has demonstrated that phosphorylation at Ser219 by PKA promotes subsequent ubiquitination by SCFβ-TrCP, leading to proteasomal degradation . This process may be further regulated by additional modifications, including phosphorylation by other kinases like NEK6 and potential interactions with modification systems like neddylation . Understanding these complex PTM networks is essential for developing targeted interventions that could modulate ATF4 function in neurological disorders.

What are the implications of ATF4 Ser219 phosphorylation in neurological disorders and potential therapeutic approaches?

The phosphorylation of ATF4 at Ser219 and its subsequent degradation represent a crucial regulatory mechanism in synaptic plasticity that may have significant implications for neurological disorders:

Pathological Relevance:

• Cognitive disorders: Dysregulation of ATF4 phosphorylation and degradation could impair the precise timing of CREB-dependent gene expression required for memory formation and cognitive function

• Neurodegenerative diseases: Several neurodegenerative conditions show alterations in proteasome function and ubiquitin-dependent protein degradation pathways that could affect ATF4 turnover

• Stress-related disorders: As a component of the integrated stress response (ISR), ATF4 regulation may be disrupted in conditions characterized by chronic stress

Therapeutic Strategies Targeting This Pathway:

• PKA modulators: Compounds that enhance PKA activity could promote ATF4 phosphorylation at Ser219 and subsequent degradation, potentially enhancing CREB-dependent gene expression

• Neddylation pathway interventions: Selective modulators of the neddylation pathway could fine-tune SCFβ-TrCP activity and ATF4 degradation rates

• β-TrCP interaction modulators: Small molecules designed to enhance or inhibit the interaction between phosphorylated ATF4 and β-TrCP could provide precise control over ATF4 degradation kinetics

Experimental Models for Therapeutic Development:

• Transgenic mouse models: Expression of phosphorylation-defective ATF4 (S219A) or phosphomimetic ATF4 (S219D) to assess cognitive and synaptic phenotypes

• Patient-derived neurons: iPSC-derived neurons from patients with cognitive disorders to assess ATF4 phosphorylation dynamics and response to potential therapeutics

• High-throughput screening platforms: Development of cell-based assays using phospho-specific antibodies to identify compounds that modulate ATF4 Ser219 phosphorylation

The critical role of ATF4 phosphorylation in regulating BDNF expression makes this pathway particularly interesting for disorders involving BDNF dysregulation, such as major depression and certain neurodevelopmental conditions. Future therapeutic approaches may aim to normalize the timing and magnitude of ATF4 phosphorylation and degradation to restore proper CREB-dependent gene expression patterns.

How can researchers leverage phospho-specific antibodies to develop ATF4 Ser219 phosphorylation as a biomarker for neuroplasticity?

Developing ATF4 Ser219 phosphorylation as a biomarker for neuroplasticity represents an emerging research direction with significant potential for both basic science and clinical applications:

Biomarker Development Strategies:

• Assay optimization:

  • Development of ultra-sensitive ELISA protocols for phospho-ATF4 detection in limited samples

  • Adaptation of Phospho-ATF4 (Ser219) antibodies for high-throughput screening platforms

  • Creation of automated image analysis algorithms for quantitative immunohistochemistry

• Translational biofluid approaches:

  • Investigation of phospho-ATF4 in cerebrospinal fluid as a potential biomarker

  • Analysis of extracellular vesicle content for phospho-ATF4 as a non-invasive sampling approach

  • Development of single-molecule detection methods for ultra-low abundance detection

Validation in Experimental Systems:

• Correlation with established plasticity markers:

  • Parallel measurement of phospho-ATF4, BDNF levels, and electrophysiological LTP

  • Multi-modal analysis combining phospho-ATF4 detection with functional imaging

  • Longitudinal studies linking early phospho-ATF4 dynamics to later plasticity outcomes

• Pharmacological validation:

  • Response of phospho-ATF4 biomarkers to known plasticity-enhancing compounds

  • Dose-dependent effects of PKA modulators on phospho-ATF4 profiles

  • Temporal profiling to establish characteristic signature patterns

Clinical Translation Potential:

• Application in intervention studies:

  • Use of phospho-ATF4 as a pharmacodynamic marker in trials of cognitive enhancers

  • Assessment of phospho-ATF4 response to non-pharmacological interventions (e.g., exercise, cognitive training)

  • Correlation between phospho-ATF4 changes and cognitive performance metrics

• Personalized medicine approaches:

  • Identification of patient subgroups with distinct phospho-ATF4 regulation patterns

  • Prediction of treatment response based on baseline phospho-ATF4 dynamics

  • Tracking of disease progression using longitudinal phospho-ATF4 measurements

Research has established that phospho-ATF4 (Ser219) follows a characteristic temporal profile during plasticity events, with significant increases occurring approximately 15-20 minutes after stimulation, followed by proteasome-dependent degradation by 30 minutes . This distinctive pattern provides a potential "molecular signature" of productive plasticity that could be developed into a biomarker with both diagnostic and prognostic value in neurological conditions affecting cognitive function.

What novel methodological approaches can improve the specificity and sensitivity of phosphorylated ATF4 (Ser219) detection in complex biological samples?

Advancing the detection of phosphorylated ATF4 (Ser219) in complex biological samples requires innovative methodological approaches that address current technical limitations:

Emerging Antibody Technologies:

• Single-domain antibodies (nanobodies):

  • Development of phospho-specific nanobodies with enhanced epitope access

  • Reduced size for improved tissue penetration in intact preparations

  • Potential for direct fluorophore conjugation without size-related steric hindrance

• Recombinant antibody engineering:

  • Creation of high-affinity recombinant antibody fragments with improved specificity

  • Site-specific conjugation strategies for optimal fluorophore positioning

  • Multimerization approaches for avidity enhancement and signal amplification

Signal Amplification Methods:

• Proximity-based amplification:

  • Proximity ligation assays (PLA) for detecting phospho-ATF4 and interacting partners

  • Rolling circle amplification for exponential signal enhancement from single binding events

  • DNA-point accumulation for imaging in nanoscale topography (DNA-PAINT) for super-resolution imaging

• Enzymatic signal enhancement:

  • Tyramide signal amplification optimized for phospho-epitopes

  • Click chemistry-based approaches for site-specific labeling and amplification

  • Hybrid enzymatic-fluorescent methods for multi-modal detection

Advanced Sample Preparation:

• Tissue clearing techniques:

  • Optimization of CLARITY, iDISCO, or CUBIC protocols for phospho-epitope preservation

  • Development of phosphatase inhibitor-enhanced clearing solutions

  • Rapid processing methods to minimize dephosphorylation during preparation

• Single-cell analysis:

  • Adaptation of scRNA-seq protocols to include phosphoprotein detection

  • Flow cytometry with highly sensitive phospho-specific detection

  • Mass cytometry (CyTOF) with phospho-specific metal-conjugated antibodies

Computational Enhancements:

• Machine learning algorithms:

  • Trained neural networks for automated phospho-signal detection and quantification

  • Deconvolution algorithms to resolve phospho-signals in complex tissues

  • Pattern recognition for identifying characteristic temporal profiles of pSer219-ATF4